Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient
Soft tissue sarcoma is a heterogeneous disease and treatment options are limited in advanced stage settings. Brivudine is a thymidine-nucleoside analog and inhibits DNA polymerase in VZV infection. We demonstrated a case of a patient who was diagnosed with both VZV infection and advanced stage sarcoma, and unexpected anti-tumoral response after brivudine therapy.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. [CrossRef]
2. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;2003:Cd003293. [CrossRef]
3. Young RJ, Natukunda A, Litière S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer 2014;50:3178–86. [CrossRef]
4. Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine). Drugs 2004;64:2091–7; discussion 8–9. [CrossRef]
5. Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:150–61.
6. Van Rompay AR, Johansson M, Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 2003;100:119–39.
7. Bitter EE, Townsend MH, Erickson R, Allen C, O'Neill KL. Thymidine kinase 1 through the ages: a comprehensive review. Cell Biosci 2020;10:138. [CrossRef]
8. Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 2010;285:27327–35. [CrossRef]
9. Jagarlamudi KK, Hansson LO, Eriksson S. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. BMC Cancer 2015;15:66.
10. Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark Med 2018;12:1035–48. [CrossRef]
11. Munch-Petersen B, Tyrsted G. Thymidine kinase isoenzymes in human acute monocytic leukemia. Mol Cell Biochem 1985;66:185–91. [CrossRef]
12. Gentry GA. Viral thymidine kinases and their relatives. Pharmacol Ther 1992;54:319–55. [CrossRef]
13. Jaamaa S, Nevala R, Jagarlamudi K, Tukiainen E, Blomqvist C, Sampo M. Serum concentration of thymidine kinase 1 (TK1) as a tumor marker in soft tissue sarcomas. Anticancer Res 2022;42:1509–15. [CrossRef]
14. Heinrich JC, Tuukkanen A, Schroeder M, Fahrig T, Fahrig R. RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol 2011;137:1349–61. [CrossRef]
15. Sloan AE, Buerki RA, Murphy C, Kelly AT, Ambady P, Brown M, et al. LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. J Clin Oncol 2021;39:TPS2065. [CrossRef]